DB:7DC

Stock Analysis Report

Executive Summary

Diaceutics Plc provides data analytics and implementation services for pharmaceutical companies worldwide.

Snowflake

Fundamentals

Reasonable growth potential with mediocre balance sheet.

Risks

  • Diaceutics is covered by less than 3 analysts.

Share Price & News

How has Diaceutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.5%

DB:7DC

-2.7%

DE Life Sciences

1.8%

DE Market


1 Year Return

n/a

DB:7DC

4.3%

DE Life Sciences

-3.5%

DE Market

No trading data on 7DC.

No trading data on 7DC.


Share holder returns

7DCIndustryMarket
7 Day0.5%-2.7%1.8%
30 Day13.6%3.3%8.6%
90 Day10.2%3.3%3.3%
1 Yearn/a5.2%4.3%-0.5%-3.5%
3 Yearn/a72.9%64.2%20.6%10.3%
5 Yearn/a217.2%192.1%30.7%12.8%

Price Volatility Vs. Market

How volatile is Diaceutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Diaceutics undervalued based on future cash flows and its price relative to the stock market?

3.63x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Diaceutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Diaceutics to establish if it is available at substantial discount.


Price Based on Earnings

Diaceutics is loss making, we can't compare its value to the Europe Life Sciences industry average.

Diaceutics is loss making, we can't compare the value of its earnings to the Germany market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Diaceutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Diaceutics is overvalued based on assets compared to the Europe Life Sciences industry average.


Next Steps

Future Growth

How is Diaceutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

150.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Diaceutics's revenue is expected to grow by 18% yearly, however this is not considered high growth (20% yearly).

Diaceutics's earnings are expected to grow significantly at over 20% yearly.

Diaceutics's revenue growth is expected to exceed the Germany market average.

Diaceutics's earnings growth is expected to exceed the Germany market average.

Diaceutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Diaceutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Diaceutics performed over the past 5 years?

-2.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Diaceutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Diaceutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Diaceutics's 1-year growth to the Europe Life Sciences industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Diaceutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

Diaceutics used its assets less efficiently than the Europe Life Sciences industry average last year based on Return on Assets.


Return on Capital Employed

It is difficult to establish if Diaceutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Diaceutics's financial position?


Financial Position Analysis

Diaceutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Diaceutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Diaceutics's level of debt (0.6%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Diaceutics's debt level has increased without past 5-year debt data.

Operating cash flow is negative therefore debt is not well covered.

Diaceutics is making a loss, therefore interest payments are not well covered by earnings.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 169.2x debt.


Next Steps

Dividend

What is Diaceutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Diaceutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Diaceutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Diaceutics has not reported any payouts.

Unable to verify if Diaceutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Diaceutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Diaceutics's salary, the management and board of directors tenure and is there insider trading?

0.3yrs

Average management tenure


CEO

Peter Keeling 0

0yrs

Tenure

0

Mr. Peter Keeling serves as Chief Executive Officer and Director of Diaceutics PLC. Mr. Keeling was Co-founder and Chief Executive at Diagnology Limited. 


Management Age and Tenure

0.3yrs

Average Tenure

The average tenure for the Diaceutics management team is less than 2 years, this suggests a new team.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Peter Keeling

    CEO & Director

    • Tenure: 0yrs
  • Damian Thornton

    Chief Operating Officer

    • Tenure: 0yrs
  • Aiya Campbell

    Financial Controller

    • Tenure: 0yrs
  • Ryan Keeling

    Chief Innovation Officer & Director

    • Tenure: 0yrs
  • Jordan Clark

    Chief Technical Officer

    • Tenure: 0yrs
  • Philip White

    CFO, Company Secretary & Director

    • Tenure: 0yrs
  • Sarah Bondi

    Senior Director of Human Resources

    • Tenure: 0yrs
  • Zarina Bibi

    General Counsel

    • Tenure: 0.3yrs
  • Susanne Munksted

    Managing Director

    • Tenure: 0.7yrs
  • Derek Hosty

    Head of Global Data

    • Tenure: 0.08yrs

Board Members

  • Julie Wallin

    Chairwoman

    • Tenure: 0yrs
  • Mike Wort (68yo)

    Non-Executive Director

    • Tenure: 0yrs
  • Peter Keeling

    CEO & Director

    • Tenure: 0yrs
  • Ryan Keeling

    Chief Innovation Officer & Director

    • Tenure: 0yrs
  • Philip White

    CFO, Company Secretary & Director

    • Tenure: 0yrs

Company Information

Diaceutics PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Diaceutics PLC
  • Ticker: 7DC
  • Exchange: DB
  • Founded:
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£65.756m
  • Listing Market Cap: UK£73.932m
  • Shares outstanding: 69.58m
  • Website: https://www.diaceutics.com

Number of Employees


Location

  • Diaceutics PLC
  • Titanic Suites
  • Enterprise House
  • Belfast
  • County Antrim
  • BT2 8FE
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
7DCDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2019
DXRXAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPMar 2019

Biography

Diaceutics Plc provides data analytics and implementation services for pharmaceutical companies worldwide. It offers diagnostic landscape services, such as patient journey, lab mapping, diagnostic regulati ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 22:32
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.